Francesco Franchi (@FFranchiMD) profile picture
FL, USA
Joined June 2012
Photo by Francesco Franchi (@FFranchiMD)Photo by Francesco Franchi (@FFranchiMD)Photo by Francesco Franchi (@FFranchiMD)Photo by Francesco Franchi (@FFranchiMD)Photo by Francesco Franchi (@FFranchiMD)Photo by Francesco Franchi (@FFranchiMD)Photo by Francesco Franchi (@FFranchiMD)Photo by Francesco Franchi (@FFranchiMD)Photo by Francesco Franchi (@FFranchiMD)Photo by Francesco Franchi (@FFranchiMD)
Francesco Franchi retweeted
In patients w/ chronic coronary syndrome requiring long-term OAC, OAC monotherapy was associated w/ reduced bleeding, CV death, & net adverse clinical events compared w/ OAC+single antiplatelet therapy. jacc.org/doi/10.1016/j.jcin.… #JACCINT @Drroxmehran @MattiaGalli10 @CMichaelGibson
1
17
1
48
4,361
Francesco Franchi retweeted
Actor Chuck Norris, the action hero and star of "Walker, Texas Ranger," has died, according to a post on his verified Instagram account. He was 86. cnn.it/4rIaJPi
238
492
124
1,648
305,268
Genotype-Guided De-Escalation of DAPT: Switching to Real-World Practic... sciencedirect.com/science/ar…
22
Francesco Franchi retweeted
Switching from Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 study is now available online, using this link you have free access for 50 days (until Oct 19) Enjoy! @JACCJournals @UFHealthJax authors.elsevier.com/a/1hgI0…
5
1
16
2,717
Francesco Franchi retweeted
Ciao, Gianluca ❤️
52
407
64
6,284
126,840
Rest in Peace My Captain. #Vialli
3
139
Francesco Franchi retweeted
Le parole del nostro campione #GianlucaVialli Riposa in pace grande uomo 💙 Un abbraccio alla tua famiglia,con sincero affetto. Da “una semplice domanda” di @alecattelan @NetflixIT
34
93
7
1,139
46,165
In pts with stable CAD pre-treated w/ticagrelor, use of cangrelor associated with no sig difference in PK/PD profiles after discontinuation of drug infusion, indicates absence of DDI. Results from SWAP-5 #AHA22 @ACCinTouch @JACCJournals
1
6
1
31
SWAP-AC study showed increased P2Y12 reactivity but reduced thrombin generation, which translated into no differences in platelet-mediated global thrombogenicity b/w DPI and ticagrelor- & prasugrel, but not clopidogrel-, based DAPT #AHA22 @ACCinTouch @JACCJournals
2
5
1
11
Compared to DAPT with aspirin and a P2Y12 inhibitor, the use of a P2Y12 inhibitor in adjunct to a vascular dose of rivaroxaban as part of a DPI strategy is associated with similar effects on platelet-mediated global thrombogenicity but reduced thrombin generation.
CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings | Journal of the American Heart Association ahajournals.org/doi/10.1161/…
Updated review on guided antiplatelet therapy in patients undergoing PCI
New evidence on perosnalized selection of antiplatelet therapy. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials academic.oup.com/eurheartj/a…
Myocardial viability testing: all STICHed up, or about to be REVIVED? | European Heart Journal | Oxford Academic academic.oup.com/eurheartj/a…